Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
The company also shared that enrollment in the pivotal clinical trial of its lead asset oral weekly risperidone (LYN-005) is on track for an initial data readout in the second half of 2023.
- The company also shared that enrollment in the pivotal clinical trial of its lead asset oral weekly risperidone (LYN-005) is on track for an initial data readout in the second half of 2023.
- Under the leadership of CEO Dr. Patricia Hurter, Lyndra finalized the design of its LYNX™ drug delivery platform.
- The company also designed and built a high-tech GMP manufacturing facility to produce the LYNX platform and initiated pivotal study of its lead asset oral weekly risperidone (LYN-005).
- Ballinger joined Lyndra in 2016, was promoted to Chief Operations Officer in 2018 and added the role of President in 2021.